Trials / Completed
CompletedNCT00043316
Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis
A Phase I/II Study of Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- InterMune · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to evaluate the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) on lung function when given to patients with cystic fibrosis by inhalation (breathed into the lungs) three times a week for 12 weeks. The FDA has not approved Interferon gamma-1b for use with cystic fibrosis patients, which is the condition being examined in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | interferon gamma-1b | 500 or 1000 mcg, inhalation, 3x per week |
Timeline
- Start date
- 2001-02-01
- Completion
- 2002-10-01
- First posted
- 2002-08-09
- Last updated
- 2007-11-01
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00043316. Inclusion in this directory is not an endorsement.